APA (7th ed.) Citation

M, W., L, T., D, G., M, K., M, G., T, M., . . . P, M. (2025). Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. European journal of nuclear medicine and molecular imaging, 52(11), 4025. https://doi.org/10.1007/s00259-025-07256-5

Chicago Style (17th ed.) Citation

M, Wenzel, et al. "Cancer-control Outcomes of Radium- 223-pretreated Lutetium- 177-PSMA Radioligand Vs. Radium- 223-naïve MCRPC Patients." European Journal of Nuclear Medicine and Molecular Imaging 52, no. 11 (2025): 4025. https://doi.org/10.1007/s00259-025-07256-5.

MLA (9th ed.) Citation

M, Wenzel, et al. "Cancer-control Outcomes of Radium- 223-pretreated Lutetium- 177-PSMA Radioligand Vs. Radium- 223-naïve MCRPC Patients." European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 11, 2025, p. 4025, https://doi.org/10.1007/s00259-025-07256-5.